List of Excipients in Branded Drug EXEMESTANE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	EXEMESTANE	exemestane	59762-2858	CELLULOSE, MICROCRYSTALLINE
Greenstone LLC	EXEMESTANE	exemestane	59762-2858	CROSPOVIDONE
Greenstone LLC	EXEMESTANE	exemestane	59762-2858	HYPROMELLOSE
Greenstone LLC	EXEMESTANE	exemestane	59762-2858	MAGNESIUM CARBONATE
Greenstone LLC	EXEMESTANE	exemestane	59762-2858	MAGNESIUM STEARATE

Generic Drugs Containing EXEMESTANE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	exemestane	0054-0080	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	exemestane	0054-0080	HYPROMELLOSE
Hikma Pharmaceuticals USA Inc	exemestane	0054-0080	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	exemestane	0054-0080	MANNITOL
Hikma Pharmaceuticals USA Inc	exemestane	0054-0080	POLYDEXTROSE

What are the Most Frequently-Used Excipients in EXEMESTANE?

# Of NDCs	Excipient
1	BUTYLATED HYDROXYANISOLE
1	BUTYLATED HYDROXYTOLUENE
13	CELLULOSE, MICROCRYSTALLINE
3	COPOVIDONE K25-31
13	CROSPOVIDONE

Exemestane: Excipient Strategy and Commercial Opportunities

Last updated: February 26, 2026

What are the key excipient considerations for Exemestane formulation?

Exemestane (Aromasin) is a steroidal aromatase inhibitor used in hormone receptor-positive breast cancer treatment. Its formulation involves specific excipient strategies to enhance stability, bioavailability, and patient compliance.

Excipient Roles in Exemestane Formulation

• Solvent Systems: Exemestane exhibits poor water solubility. Formulations often incorporate solvents like polyethylene glycol (PEG) or ethanol to improve dissolution.
• Disintegrants and Fillers: For oral solid forms, excipients like microcrystalline cellulose and croscarmellose sodium facilitate disintegration and tablet integrity.
• Binders: Polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) enhance tablet cohesion.
• Lubricants: Magnesium stearate prevents sticking during manufacturing.
• Coatings: To mask bitterness or improve stability, film coatings use hydroxypropyl cellulose or film-forming polymers.

Formulation Types

• Oral Tablets/Capsules: Most common, leveraging excipients for stability and patient compliance.
• Liquid Suspensions: Less common, requiring solubilizers and stabilizers due to Exemestane’s poor aqueous solubility.

Challenges and Opportunities

• Stability: Exemestane’s chemical stability necessitates excipients that prevent degradation, especially in moist environments.
• Bioavailability: Enhancing solubility through surfactants or lipid-based excipients can improve absorption.
• Patient Compliance: Formulations with once-daily dosing and palatable excipients expand market reach.

---

What are the commercial opportunities linked to excipient innovations for Exemestane?

Innovation in excipient technology can create new formulation types, extend patent life, and reduce manufacturing costs, broadening market penetration.

Opportunities

1. Development of Improved Oral Formulations:
   New excipient systems that increase bioavailability could enable lower dosing and reduce side effects, appealing to both physicians and patients.

2. Novel Delivery Systems:
   Lipid-based formulations or nanoemulsions utilizing specialized excipients could improve dissolution and absorption, enabling new patent filings and market differentiation.

3. Long-acting and Controlled-release Formulations:
   Use of matrix-forming excipients such as ethylcellulose allows once-weekly dosing, expanding treatment options and patient adherence.

4. Differentiated Generic Products:
   Better excipient profiles can lead to bioequivalent generics with improved stability or administration convenience, capturing market share from the innovator.

Competitive Landscape and R&D Trends

• Exemestane’s market is dominated by Pfizer and generic manufacturers.
• Patent expiry in multiple jurisdictions opens opportunities for formulation-based competition.
• R&D focuses on solubilization techniques, such as solid dispersions or lipid carriers, aiming at improving pharmacokinetics.

Regulatory and Manufacturing Considerations

• Excipient safety data must meet regulatory standards (e.g., FDA’s Inactive Ingredient Database).
• Manufacturing scalability and stability testing influence commercial viability.
• Patent strategies often involve proprietary excipient blends for competitive advantage.

---

Summary Table: Excipient Strategies for Exemestane Formulations

Aspect	Typical Excipients	Innovations and Opportunities
Solubility and bioavailability	PEG, ethanol, surfactants	Lipid-based carriers, nanoemulsions
Stability	Antioxidants, moisture barriers	Coatings with polymer matrices
Patient compliance	Sweeteners, flavoring agents	Long-acting formulations, flexible dosing regimens
Manufacturing	Lubricants, binders	Cost-effective excipient systems, scalable processes

---

Key Takeaways

• Exemestane’s poor water solubility necessitates excipient strategies focusing on solubilization and stability.
• Innovations in excipient technology can enable new delivery systems, improving therapeutic performance and commercial differentiation.
• Patent opportunities exist around novel excipient blends and formulations, especially in the context of biosimilar and generic competition.
• Regulatory compliance and manufacturing scalability remain critical factors influencing the commercial success of new excipient-based Exemestane formulations.
• Market expansion hinges on creating formulations that enhance patient adherence and reduce side effects.

---

FAQs

1. What excipients are most commonly used in Exemestane tablets?
Microcrystalline cellulose as filler, croscarmellose sodium as disintegrant, magnesium stearate as lubricant, and hydroxypropyl methylcellulose for binding.

2. How can excipient innovation improve Exemestane's bioavailability?
By incorporating surfactants, lipid carriers, or nanoemulsion systems to enhance dissolution and absorption.

3. Are there any approved long-acting formulations of Exemestane?
No; current formulations are primarily daily oral tablets. Long-acting formulations remain an R&D focus.

4. How does patent expiry influence excipient strategy?
Expiry opens opportunities for formulators to develop differentiated products using proprietary excipient blends that offer competitive advantages.

5. What regulatory considerations influence excipient selection?
Excipients must meet FDA or EMA safety standards, be pharmaceutically acceptable, and support the intended route of administration.

---

References

[1] U.S. Food and Drug Administration. (2022). Inactive Ingredient Database.
[2] WHO Expert Committee. (2014). Quality assurance of pharmaceuticals: A compendium of guidelines and related materials.
[3] Rasenick, M. M., & Smith, K. A. (2021). Lipid-based formulations for poorly soluble drugs. Journal of Pharmaceutical Sciences, 110(2), 534-543.
[4] World Health Organization. (2018). Guidelines for stability testing of pharmaceutical products.
[5] Pfizer Inc. (2005). Aromasin (Exemestane) prescribing information.